Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer’s,” Charles Piller looks how the amyloid hypothesis took over ...
Zacks.com on MSN15h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
thearabianpost on MSN17h
Monoclonal Antibodies: A New Era in Alzheimer’s TreatmentMonoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback